22/01/2025 – AB Science announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors, that will take place on February 4, 2025, in Paris Download PDF Post navigationPreviousPrevious post:Summary of the webcast held on December 16, 2024NextNext post:Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CETRelated PostsEuropean Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseApril 14, 2025Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025Summary of the webcast held on January 28, 2025January 29, 2025AB Science webcast of January 28, 2025January 29, 2025Live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CETJanuary 24, 2025
European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseApril 14, 2025
Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025
